American Journal of Respiratory and Critical Care Medicine

To investigate whether the effects of in utero exposure to maternal smoking and environmental tobacco smoke (ETS) exposure on lung function vary by sex or asthma status, we examined medical history and tobacco smoke exposure data for 5,263 participants in the Children's Health Study. At study enrollment, parents or guardians of each subject completed a questionnaire, and lung function was measured spirometrically with maximum forced expiratory flow–volume maneuvers. To assess the in utero effects of maternal smoking and ETS exposure on lung function, we used regression splines that accounted for the nonlinear relationship between pulmonary function, height, and age. In utero exposure to maternal smoking was independently associated with deficits in lung function that were larger for children with asthma. Boys and girls with a history of in utero exposure to maternal smoking showed deficits in maximum midexpiratory flow (MMEF) and a decrease in the FEV1/FVC ratio. As compared with children without asthma, boys with asthma had significantly larger deficits from in utero exposure in FVC, MMEF, and FEV1/FVC, and girls with asthma had larger decreases in FEV1/FVC. The effect of ETS exposure varied by children's gender and asthma status. Deficits in flows associated with current ETS exposure were present in children with and without asthma but were significant only among children without asthma. Past ETS exposure was associated with reduced FEV1, MMEF, and FEV1/FVC among boys with asthma. In contrast, past ETS exposure was associated with decreased flow rates in girls without asthma. In summary, both in utero exposure to maternal smoking and ETS exposure were associated with persistent deficits in lung function. The effects of in utero exposure were greatest among children with asthma.

A growing body of scientific evidence indicates that childhood environmental tobacco smoke (ETS) exposure adversely affects lung function, and especially measured indicators of flow, such as FEV1 and maximum midexpiratory flow (MMEF) (1– 7). Although studies consistently associate ETS exposure with deficits in lung function, interpretation of these findings requires consideration of in utero exposure to maternal smoking, which is associated with deficits in lung function at birth that may persist into young adulthood (4, 6, 8-15). However, remarkably few studies of the effect of ETS on lung function have investigated effects of in utero exposure to maternal smoking. The findings in studies that have investigated in utero effects on lung function are inconsistent, and the independent and joint effects of ETS and in utero exposure are uncertain. A clearer understanding of the effects of tobacco smoke exposures during the in utero and postnatal periods is needed.

The inconsistency in results for the independent and joint effects of ETS and in utero exposure on lung function may arise from variation in the proportion of sensitive children in the study population. Children with asthma are particularly sensitive to effects of ETS exposure during the postnatal period, and are more prone to the acute effects of ETS than are children without asthma (2). Children with asthma who are exposed in utero to maternal smoking may have large deficits because the effects of in utero exposure on lung function may add to chronic deficits from asthma (16). Although the combination of in utero and ETS exposures may be of particular importance for children with asthma, and may explain some of the inconsistencies among studies, the effects of in utero exposure on boys and girls with asthma have not been extensively investigated.

The University of Southern California Children's Health Study (CHS), an ongoing study in California, offers an opportunity to further investigate the modifying effects of asthma and sex on deficits in lung function associated with in utero exposure to maternal cigarette smoking and childhood ETS exposures. We examined cross-sectional data from the CHS to assess the relationships between lung function, asthma, in utero exposure to maternal smoking, and ETS exposures in boys and girls, using regression spline techniques.

Study Design

The CHS is a 10-yr longitudinal study of schoolchildrens' respiratory health. Details of the study design, site selection, subject recruitment, and assessment of health effects in the study are reported elsewhere (17, 18). At study entry, in the spring of 1993, a parent or guardian of each participating child provided written informed consent and completed a self-administered questionnaire on demographics, medical and family health history, indoor air exposures, and household characteristics. In the spring of 1993 and in each subsequent year of the ongoing study, each child completed an update questionnaire, and pulmonary function testing (PFT) was conducted. In the fall of 1995, a second group of fourth grade students was recruited and completed the same baseline and follow-up questionnaires and PFT as the group enrolled in 1993. Of the 5,762 children participating in the study, both baseline questionnaire data and lung function measurements were available for 5,263 (91.3%) children (approximately 68% of whom were fourth-graders with an age range of 7 to 13 yr; 16% of whom were seventh-graders with an age range of 11 to 15 yr; and 16% of whom were tenth-graders with an age range of 14 to 19 yr) (Table 1). In the study reported here, we examined cross-sectional data collected at study entry.

Table 1. PARTICIPANT CHARACTERISTICS BY ASTHMA STATUS AND SEX

BoysGirls
All Subjects n (%)Asthmatics n (%)All Subjects n (%)Asthmatics n (%)
Total Missing* 2,586    0442 (17.1)71
2,677    0307 (11.5)75
Grade
  4 (accrued in 1993)842 (32.6)148 (33.5) 816 (30.5) 75 (24.4)
  4 (accrued in 1995)958 (37.0)164 (37.1) 954 (35.6)111 (36.2)
  7387 (15.0) 67 (15.2) 473 (17.7) 57 (18.6)
 10399 (15.4) 63 (14.2) 434 (16.2) 64 (20.8)
Race/ethnicity
 Non-Hispanic white1,468 (57.9)255 (58.1) 1,458 (55.6)179 (58.5)
 Hispanic661 (26.1) 97 (22.1) 726 (27.7) 78 (25.5)
 Black111 (4.4) 29 (6.6)148 (5.6) 21 (6.9)
 Asian137 (5.4) 26 (5.9)124 (4.7) 11 (3.6)
 Other158 (6.2) 32 (7.3)166 (6.3) 17 (5.5)
Parental education
 Some graduate education299 (12.0) 46 (10.5)  276 (10.8) 33 (10.9)
 College264 (10.6) 48 (11.0) 276 (10.8) 31 (10.2)
 Some college1,100 (44.3)222 (50.8)1,067 (41.8)135 (44.7)
 12 grades493 (19.9) 81 (18.5) 548 (21.5) 74 (24.5)
 < 12 grades326 (13.1) 40 (9.2) 387 (15.2) 29 (9.6)
Income
 > $100,000153 (7.0) 24 (6.1)133 (6.2) 15 (5.8)
 $50,000 ∼ $99,999728 (33.4)154 (39.0) 732 (34.0)100 (38.9)
 $30,000 ∼ $49,999593 (27.2)109 (27.6) 545 (25.3) 60 (23.4)
 $15,000 ∼ $29,999343 (15.7) 56 (14.2) 363 (16.9) 46 (17.9)
 $7,500 ∼ $14,999230 (10.5) 29 (7.3) 248 (11.5) 22 (8.6)
 < $7,500134 (6.1) 23 (5.8)130 (6.0) 14 (5.4)
Medical insurance
 No351 (14.1)36 (8.3)  443 (17.1) 31 (10.4)
 Yes2,147 (85.9)400 (91.7)2,145 (82.9)267 (89.6)
Smoke exposure
 None1,430 (60.1)247 (59.5)1,430 (57.3)149 (51.0)
 Past ETS only234 (9.8) 38 (9.2) 300 (12.0) 33 (11.3)
 Past and current ETS only277 (11.6) 49 (11.8) 295 (11.8) 34 (11.6)
In utero only75 (3.2) 19 (4.6) 72 (2.9) 13 (4.5)
In utero and ETS363 (15.3) 62 (14.9) 400 (16.0) 63 (21.6)
Personal smoking
 No2,535 (98.0)435 (98.4)2,630 (98.2)301 (98.1)
 Yes51 (2.0)  7 (1.6) 47 (1.8)  6 (1.9)

Definition of abbreviation: ETS = environmental tobacco smoke.

* Subjects with missing data were excluded from corresponding analyses.

p < 0.05 for comparison of factor between boys or girls with and without asthma:

p < 0.001 for comparison of factor between boys or girls with and without asthma.

Sociodemographic, Medical History, and Exposure Data

The CHS questionnaire provided information on sociodemographic factors, history of respiratory illness and its associated risk factors, exposure to ETS, and maternal smoking history. Current and past exposure to household ETS and prenatal exposure to maternal smoking were characterized from information on the current and past smoking status of each participant's mother, father, other adult household members, and regular household visitors. We defined past exposure only to household ETS as exposure to ETS in the past, but without current exposure to smokers in the household. Current ETS exposure was categorized as either the presence of only one or of two or more smokers in the household. To assess the joint effects of ETS and in utero smoking on lung function, we defined a new variable with five mutually exclusive categories: no ETS and no in utero smoking, past ETS only, past and current ETS only, in utero exposure to smoking only, and both in utero exposure to smoking and ETS.

Asthma was defined by a parent-reported history of physician-diagnosed asthma. Subject with current asthma included children with a history of physician-diagnosed asthma who had asthma symptoms or who had used medications for asthma in the 12 mo prior to completion of the study questionnaire.

Lung Function

The lung function testing and data management procedures used in the study have been reported previously (17, 18). Briefly, most PFT (92.5%) was completed during the morning hours of the spring months, in order to avoid daily and annual peak pollution periods. FVC, FEV1, the FEV1 to FVC ratio (FEV1/FVC), and MMEF were determined from maximum forced expiratory flow–volume maneuvers that were recorded with rolling-seal spirometers (Spiroflow; P.K. Morgan Ltd., Gillingham, UK). Spirometer calibrations were made just before, during, and just after each testing session, using flow–volume syringes (Jones Medical Instrument Co., Oak Brook, IL), and variables for individual spirometers and technicians were included in the statistical models. Each subject was asked to perform at least three satisfactory maneuvers. No more than seven maneuvers were attempted during any test session. At the time of testing, subject's height and weight were measured according to standard protocols, and subjects were interviewed privately about personal smoking habits, recent history of respiratory illness, and inhaler use, and whether they had performed vigorous exercise within half an hour before the test.

Statistical Analyses

The relationships between lung function and physiologic growth factors such as age and height have been found to be highly nonlinear from childhood through adolescence (19, 20). We used regression splines to capture the nonlinear relationship between pulmonary function, age, and height, and to assess the individual and joint effects of in utero exposure to maternal smoking and ETS on pulmonary function levels (11, 19, 20). The regression splines fit piecewise polynomials that are joined smoothly at the cutpoints between each regression, known as knots. This has the advantage of allowing appropriate statistical inference while capturing the nonlinear relationships in the data. Initially, a knot was placed at each integer age. The final models were fitted by using knots at ages 11, 13, 15, and 17 yr, leading to a more parsimonious model with essentially the same results.

All models were fitted separately for males and females, since the two sexes' smoothing shapes for the relationship between lung function and age are different. The sex-specific additive model was given as: E {log (PFT)} = μ + S1 (AGE) + S2 (AGE) × log (HT) + Xβ, where PFT is a pulmonary function test such as the FVC or FEV1 test; μ is the overall mean; S1 (AGE) is the smooth function of age at testing, depicting the age-dependent intercepts of height; S2 (AGE) × log (HT) is the smooth function of the age-dependent slope of height on PFT, where HT is the residual of height at visit after smoothing of the height; and X is a vector of covariates including the smoking exposure of interest and a set of adjustment variables including school grade, community, technician, spirometer, race/ethnicity, barometric pressure, and other possible confounders. This model is an example of the varying-coefficient modeling strategy of Hastie and Tibshirani (21). We used natural cubic splines that impose the additional constraint of requiring the function described by each polynomial to be linear beyond the boundary knots. Because our models are additive on the logarithmic scale, we give model results in terms of percent change ([eβ − 1] · 100%) from the appropriate reference group. Using our model, we calculated mean PFT levels for the unexposed reference group among children with and without asthma (Table 2).

Table 2. BASELINE LUNG FUNCTION LEVEL IN CHILDREN WITH AND WITHOUT ASTHMA*

Lung FunctionNo AsthmaAsthma
nml95% CInml95% CI
Boys
 FVC 1,6362,165(2,015, 2,327)3472,272(2,083, 2,478)
 FEV1 1,6341,938(1,804, 2,082)3471,868(1,675, 2,083)
 MMEF1,6232,268(1,952, 2,637)3451,940(1,517, 2,481)
Girls
 FVC1,8101,906(1,782, 2,038)2201,944(1,730, 2,183)
 FEV1 1,8051,671(1,562, 1,788)2181,696(1,519, 1,895)
 MMEF1,7902,060(1,793, 2,368)2181,962(1,534, 2,510)

Definition of abbreviations: CI = confidence interval; MMEF = median midexpiratory flow.

* Models are adjusted for community, grade, spirometer, pressure, technician, log (height), age, and race.

Among participants without in utero exposure to maternal smoking.

We performed univariate analyses and assessed each possible confounder of the relationship between tobacco smoke exposure and lung function. Subjects with missing data for a given covariate were excluded from the analyses involving that covariate. On the basis of previous analyses, parental education (< 12 grades, 12 grades, some college, college, and some graduate education), household income (< $7,500, $7,500 to $14,999, $15,000 to $29,999, $30,000 to $49,999, $50,000 to 99,999, and > $100,000), body mass index (BMI; kg/m2, by age- and sex-specific quintiles), low birth weight (< 5 lb., ⩾ 5 lb.), early chest illness excluding asthma (any before 2 yr of age versus none), insurance status (yes/no), hay fever (any versus none), house water damage (yes/no), live plants in the house (yes/no), vigorous exercise within half an hour before PFT (yes/no), and respiratory illness at PFT (yes/ no) were evaluated as potential confounders. Variables were included in models if the adjusted estimates differed by 10% or more from the unadjusted estimates. We assessed history of asthma as a potential effect modifier of the tobacco smoke effects by using stratified models and by testing the significance of an interaction term in the models. All analyses were done with the S-Plus statistical package (MathSoft Inc., Seattle, WA) (22).

Questionnaires and lung function tests were completed by 5,263 students (approximately 49% boys and 51% girls) in the 12 study communities (Table 1). Boys' ages ranged from 7 to 19 yr (fourth-grade students: mean age: 10.0 yr, age range: 7 to 13 yr; seventh-grade students: mean age: 13.1 yr, age range: 11 to 15 yr; tenth-grade students: mean age: 16.1 yr, age range: 14 to 19 yr); girls' ages ranged from 7 to 18 yr (fourth grade students: mean age: 9.9 yr, age range: 7 to 13 yr; seventh grade students: mean age: 13.0 yr, age range: 11 to 15 yr; tenth grade students: mean age: 16.0 yr, age range: 14 to 18 yr).

Among both boys and girls, the majority of participants were non-Hispanic white 4th grade students, from families with at least one parent who was a high school graduate, and had medical insurance. Participants' families were generally of middle class status on the basis of household incomes. Approximately 60% were never exposed to household ETS. About 3% of children were exposed only during the in utero period, and 12% had ETS exposure at the time of the study, but had not had in utero exposure. Few children were smokers themselves, reflecting the young ages of most participants. Overall, children with asthma came from families with a higher level of education, and had more insurance. The distribution of ethnicity, educational attainment, and insurance differed significantly between boys in whom asthma was ever diagnosed and those without asthma. There were fewer Hispanic and more black children than non-Hispanic white children with asthma. Girls in whom asthma was ever diagnosed were less likely to be in fourth grade and were more likely to have insurance and tobacco smoke exposure than were girls without asthma.

Past and current ETS exposures were approximately the same in boys with and without asthma and girls with and without asthma. The proportions of boys and girls exposed only to maternal smoking in utero were greater for those with asthma than for those without asthma. In utero and ETS exposure were lower for boys with than for those without asthma, but were higher for girls with asthma.

Table 2 shows mean baseline lung function in boys and girls with and without asthma who had no in utero exposure to maternal smoking. The levels were adjusted for community, grade, barometric pressure, height, age, and race/ethnicity. Estimates and 95% confidence intervals (CIs) are presented for non-Hispanic white children in Grade 4 who were 10 yr of age. Both boys and girls with asthma had higher FVC and lower MMEF values than did children without asthma. Girls with asthma had slightly larger FVC and FEV1 values than did girls without asthma, but the CIs for the two groups were broad and overlapping. Girls with asthma had a FEV1/FVC ratio of 0.88 (95% CI: 0.82 to 0.94) compared with 0.89 (95% CI 0.86 to 0.92) for girls without asthma. Among boys with and without asthma the FEV1/FVC ratios were 0.82 (95% CI: 0.77 to 0.88) and 0.90 (95% CI: 0.86 to 0.93), respectively.

In utero exposure to maternal smoking was associated with deficits in lung function, especially among children with asthma (Table 3). Boys with a history of in utero exposure to maternal smoking showed deficits in FEV1 and MMEF, as well as decreases in the FEV1/FVC ratio, as compared with those without in utero exposure. Girls with a history of in utero exposure showed deficits in MMEF as well as decreases in the FEV1/FVC ratio as compared with those without in utero exposure. As compared with children without asthma, boys with asthma had significantly larger deficits from in utero exposure in FVC (1.4% versus −4.3%), FEV1 (−0.2% versus −7.1%), and MMEF (−4.2% versus −11.3%). Girls with asthma had larger decreases in FEV1/FVC (−1.2% versus −3.6%) and MMEF (−3.0% versus −8.7%), and had a larger increase in FVC (1.0% versus 3.3%) than did those without asthma. The decreases in FEV1/FVC resulted from an increase in estimated FVC and a decrease in estimated FEV1. The effects of in utero exposure on lung function did not vary by age (data not shown). Parental education, household income, insurance status, current or past ETS exposure, or personal smoking did not confound the relationship between in utero exposure and lung function.

Table 3. EFFECTS OF IN UTERO EXPOSURE TO MATERNAL SMOKING ON LUNG FUNCTION LEVEL IN CHILDREN WITH AND WITHOUT ASTHMA*

Lung FunctionAllNo AsthmaAsthma
n ** % Change95% CIn% Change95% CIn% Change95% CI
Boys
 FVC 444/2,0050.3(−0.8, 1.5)351/1,6361.4 (0.1, 2.7)82/347−4.3 (−7.2, −1.3)
 FEV1 442/2,003−1.6 (−2.8, −0.3)350/1,634−0.2(−1.5, 1.1)82/347−7.1§ (−10.7, −3.3)
 FEV1/FVC442/2,003−2.0§ (−2.7, −1.2)350/1,634−1.6§ (−2.4, −0.9)82/347−2.9 (−5.2, −0.6)
 MMEF 438/1,990−5.9§ (−8.4, −3.4)347/1,623−4.2 (−6.7, −1.6)82/345−11.3 (−18.7, −3.2)
Girls
 FVC480/2,0611.5 (0.3, 2.7)397/1,8101.0(−0.3, 2.3)78/2203.3 (0.2, 6.5)
 FEV1 479/2,054−0.3(−1.5, 0.9)396/1,805−0.3(−1.6, 1.0)78/218−0.5(−3.6, 2.8)
 FEV1/FVC 479/2,054−1.7§ (−2.3, −1.0)396/1,805−1.2§ (−1.9, −0.5)78/218−3.6§ (−5.7, −1.6)
 MMEF473/2,039−3.9 (−6.3, −1.5)392/1,790−3.0 (−5.6, −0.3)76/218−8.7 (−15.2, −1.7)

Definition of abbreviations: CI = confidence interval; FEV1/FVC = ratio of FEV1 to FVC; MMEF = median midexpiratory flow.

* Models are adjusted for community, grade, spirometer, pressure, technician, log (height), age, and race.

p < 0.05, percent change from boys and girls without in utero exposure.

p < 0.01, percent change from boys and girls without in utero exposure.

§ p < 0.001, percent change from boys and girls without in utero exposure.

Significant difference in effect of in utero exposure by asthma status (p < 0.05).

** Exposed/unexposed.

Exposure to ETS was associated with deficits in lung flows and increases in lung volumes; however, the effects of past and current ETS exposure varied by children's asthma status (Table 4). Both boys and girls with past exposure or current exposure showed significantly decreased flow rates, as well as increases in FVC that reached statistical significance in girls. The effects of current exposure on lung flow rates were apparent for both boys and girls with and without asthma, but the deficits in flow rates were significant only for children without asthma. Exclusively past exposure was associated with different effects in boys and girls. Past ETS exposure was associated with reduced FEV1 (−4.9%), MMEF (−9.2%), and FEV1/ FVC (−2.8%) among boys with asthma. No effect of past exposure was found among boys without asthma. In contrast, past ETS exposure was associated with reduced lung function in girls without asthma, but not in girls with asthma, for whom estimates were imprecise owing to the small size of this group. The effects followed the same pattern among children with current asthma, but were not as significant because of the smaller number of children with current asthma (data not shown). The effects of two or more current smokers in the household were generally larger than the effects associated with one current smoker, except for FEV1 in both boys and girls. Parental education, household income, or insurance status did not confound the relationship between the number of smokers in the household and lung function.

Table 4. EFFECTS OF ENVIRONMENTAL TOBACCO SMOKE EXPOSURE ON LUNG FUNCTION LEVEL IN CHILDREN WITH AND WITHOUT ASTHMA*

Lung FunctionSmoke ExposureAllNo AsthmaAsthma
n% Change95% CIn% Change95% CIn% Change95% CI
Boys
 FVCNone1,450ref1,187ref251ref
Past ETS only432−0.6(−1.8, 0.6)348−0.3(−1.6, 1.0) 76−2.2(−5.4, 1.1)
One current smoker352−1.1(−2.4, 0.2)286−0.6(−2.0, 0.9) 59−3.3(−6.9, 0.4)
Two or more current smokers1551.7(−0.2, 3.7)1231.6(−0.6, 3.8) 290.8(−4.2, 6.0)
 FEV1 None1,449ref1,186ref251ref
Past ETS only 430−1.3 (−2.6, −0.1)346−0.5(−1.8, 0.9) 76−4.9 (−8.9, −0.7)
One current smoker351−1.5 (−2.9, −0.1)286−1.1(−2.5, 0.3) 59−3.9(−8.4, 0.9)
Two or more current smokers155−0.3(−2.4, 1.8)1230.1(−2.0, 2.2) 29−2.9(−9.0, 3.7)
 FEV1/FVCNone1,449ref1,186ref251ref
Past ETS only 430−0.8(−1.5, 0.1)346−0.2(−1.0, 0.6) 76−2.8 (−5.2, −0.3)
One current smoker351−0.4(−1.3, 0.4)286−0.6(−1.4, 0.3) 59−0.6(−3.3, 2.3)
Two or more current smokers155−2.0 (−3.2, −0.8)123−1.5 (−2.8, −0.3) 29−3.6(−7.2, 0.1)
 MMEFNone1,440ref1,177ref251ref
Past ETS only425−2.2(−4.9, 0.6)343−0.5(−3.2, 2.3) 75−9.2 (−17.2, −0.4)
One current smoker350−2.7(−5.6, 0.3)285−2.7(−5.6, 0.3) 59−4.0(−13.4, 6.5)
Two or more current smokers153−5.0 (−9.1, −0.7)122−4.5 (−8.6, −0.2) 28−5.2(−17.7, 9.5)
Girls
 FVCNone1,443ref1,273ref151ref
Past ETS only5120.8(−0.4, 2.0)4370.5(−0.8, 1.8) 702.5(−0.8, 6.0)
One current smoker3550.9(−0.4, 2.3)3040.6(−0.9, 2.1) 441.9(−2.2, 6.1)
Two or more current smokers1792.4 (0.5, 4.3)1471.4(−0.7, 3.5) 305.9 (1.2, 10.9)
 FEV1 None1,439ref1,271ref149ref
Past ETS only512−0.1(−1.3, 1.1)437−0.4(−1.7, 0.9) 702.1(−1.5, 5.7)
One current smoker3510.4(−1.0, 1.8)3000.2(−1.3, 1.7) 441.1(−3.2, 5.6)
Two or more current smokers1790.2(−1.6, 2.1)147−0.5(−2.5, 1.6) 302.7(−2.3, 7.8)
 FEV1/FVCNone1,439ref1,271ref149ref
Past ETS only512−0.8§ (−1.4, −0.1)437−0.9§ (−1.6, −0.2) 70−0.2(−2.5, 2.3)
One current smoker351−0.8(−1.6, 0.1)300−0.7(−1.6, 0.1) 44−0.8(−3.7, 2.2)
Two or more current smokers179−2.0§ (−3.0, −1.0)147−1.8 (−2.9, −0.7) 30−2.7(−6.0, 0.6)
 MMEFNone1,431ref1,263ref149ref
Past ETS only505−2.6 (−5.0, −0.2)431−3.2 (−5.7, −0.6) 691.4(−6.5, 10.0)
One current smoker346−0.9(−3.7, 2.1)296−2.2(−5.2, 0.9) 437.0(−3.3, 18.4)
Two or more current smokers178−5.3 (−9.0, −1.5)146−5.9 (−9.8, −1.7) 30−4.2(−14.4, 7.2)

Definition of abbreviations: CI = confidence interval; ETS = environmental tobacco smoke; FEV1/FVC = ratio of FEV1 to FVC; MMEF = median midexpiratory flow.

* Models are adjusted for community, grade, spirometer, pressure, technician, log (height), age, and race.

p < 0.05, percent change from boys and girls without in utero exposure.

p < 0.01, percent change from boys and girls without in utero exposure.

§ p < 0.001, percent change from boys and girls without in utero exposure.

p < 0.05 for comparison between children with and without asthma.

On the basis of analyses done with mutually exclusive exposure categories, in utero exposure to maternal smoking was independently associated with deficits that were particularly apparent in boys and girls with asthma (Table 5). Although a limited number of participants had in utero exposure only, we found that children with a history of in utero exposure only or of both in utero exposure and postnatal ETS exposure had deficits of about 5% in MMEF, as well as decreases in the FEV1/FVC ratio. The effect of in utero exposure alone was greatest for children with asthma. Boys with asthma who were exposed in utero had a 14% deficit in MMEF and a 5% decrease in the FEV1/FVC ratio as compared with boys with asthma who were not exposed. Girls with asthma had a 17% deficit in MMEF and a 7% decrease in the FEV1/FVC ratio as compared with girls who were not exposed. In utero exposure was also associated with a small but significant increase in FVC in girls, largely due to its effect among girls with asthma. In contrast, boys with asthma had a significant deficit in FVC associated with in utero exposure.

Table 5. EFFECTS OF IN UTERO AND ENVIRONMENTAL TOBACCO SMOKE EXPOSURE ON LUNG FUNCTION LEVEL IN CHILDREN WITH AND WITHOUT ASTHMA

Lung FunctionSmoke ExposureAllNo AsthmaAsthma
n% Change95% CIn% Change95% CIn% Change95% CI
Boys
 FVCNone1,415ref1,158ref245ref
Past ETS only233−1.4(−2.9, 0.2)192−1.3(−2.9, 0.4) 38−2.1(−6.3, 2.3)
Current ETS274−0.9(−2.4, 0.6)222−1.4(−2.9, 0.3) 491.3(−2.7, 5.4)
In utero only 74−0.7(−3.3, 1.9) 53−0.5(−3.4, 2.6) 19−1.9(−7.6, 4.1)
In utero + ETS** 3590.3(−1.0, 1.7)2901.5 (0.0, 2.9) 61−4.6 (−7.9, −1.1)
 FEV1 None1,414ref1,157ref245ref
Past ETS only232−1.1(−2.7, 0.6)191−0.7(−2.3, 1.0) 38−2.7(−8.1, 3.0)
Current ETS274−1.0(−2.5, 0.6)222−1.1(−2.6, 0.5) 49−0.4(−5.5, 4.9)
In utero only 74−2.3(−5.0, 0.4) 53−0.4(−3.3, 2.7) 19−6.8(−13.8, 0.7)
In utero + ETS** 357−1.6 (−3.0, −0.2)289−0.3(−1.7, 1.1) 61−7.2 (−11.4, −2.8)
 FEV1/FVCNone1,414ref1,157ref245ref
Past ETS only2320.3(−0.7, 1.3)1910.5(−0.5, 1.5) 38−0.6(−3.8, 2.8)
Current ETS274−0.1(−1.0, 0.9)2220.3(−0.7, 1.2) 49−1.7(−4.6, 1.4)
In utero only  74−1.6(−3.3, 0.1) 530.1(−1.7, 1.9) 19−5.0 (−9.2, −0.6)
In utero + ETS 357−2.0 (−2.8, −1.2)289−1.8§ (−2.7, −1.0) 61−2.8 (−5.4, −0.1)
 MMEFNone1,405ref1,148ref245ref
Past ETS only2300.6(−3.0, 4.3)1901.3(−2.2, 4.9) 37−2.8(−14.2, 10.0)
Current ETS272−1.1(−4.4, 2.4)221−0.6(−3.9, 2.8) 48−2.9(−13.3, 8.6)
In utero only 72−4.9(−10.5, 1.1) 52−0.3(−6.4, 6.3) 19−14.0(−27.3, 1.7)
In utero + ETS 355−6.1§ (−8.9, −3.2)287−4.8§ (−7.6, −1.9) 61−11.0 (−19.5, −1.6)
Girls
 FVCNone1,412ref1,247ref148ref
Past ETS only 2960.5(−1.0, 2.0)2590.5(−1.1, 2.1) 331.0(−3.5, 5.6)
Current ETS 2910.6(−0.9, 2.1)2480.2(−1.4, 1.8) 342.4(−2.1, 7.0)
In utero only  722.3(−0.5, 5.2) 580.9(−2.1, 4.1) 138.5 (1.3, 16.1)
In utero + ETS  3981.4 (0.1, 2.8)3321.0(−0.5, 2.5) 633.0(−0.6, 6.7)
 FEV1 None1,408ref1,245ref146ref
Past ETS only2960.0(−1.5, 1.5)259−0.4(−2.0, 1.2) 332.7(−2.1, 7.8)
Current ETS2880.4(−1.1, 1.9)245−0.2(−1.8, 1.5) 313.3(−1.5, 8.3)
In utero only 72−0.1(−2.9, 2.7) 58−0.3(−3.4, 2.9) 131.3(−5.7, 8.9)
In utero + ETS 397−0.3(−1.7, 1.0)331−0.5(−1.9, 1.0) 630.2(−3.4, 4.0)
 FEV1/FVCNone1,408ref1,245ref146ref
Past ETS only296−0.4(−1.2, 0.5)259−0.8(−1.7, 0.1) 332.4(−0.8, 5.7)
Current ETS288−0.4(−1.3, 0.5)245−0.7(−1.6, 0.2) 310.9(−2.2, 4.1)
In utero only  72−2.3 (−3.8, −0.7) 58−1.1(−2.8, 0.6) 13−6.8 (−11.2, −2.3)
In utero + ETS 397−1.7§ (−2.4, −0.9)331−1.4§ (−2.2, −0.6) 63−2.6 (−4.9, −0.1)
 MMEFNone1,400ref1,237ref146ref
Past ETS only 292−2.1(−5.1, 1.0)255−3.6 (−6.7, −0.3) 3310.3(−0.9, 22.7)
Current ETS 285−0.5(−3.7, 2.7)242−2.4(−5.7, 1.0) 3410.2(−0.9, 22.5)
In utero only 71−6.2 (−11.6, −0.5) 57−3.2(−9.3, 3.3) 13−17.1 (−29.5, −2.6)
In utero + ETS 392−4.1 (−6.8, −1.4)328−4.1 (−7.0, −1.3) 61−3.5(−11.3, 5.0)

Definition of abbreviations: CI = confidence interval; ETS = environmental tobacco smoke; FEV1/FVC = ratio of FEV1 to FVC; MMEF = median midexpiratory flow.

* Models are adjusted for community, grade, spirometer, pressure, technician, log (height), age, and race.

p < 0.05, percent change from boys and girls without in utero exposure.

p < 0.01, percent change from boys and girls without in utero exposure.

§ p < 0.001, percent change from boys and girls without in utero exposure.

p < 0.05, for comparison between children with and without asthma.

** p < 0.01 for comparison between children with and without asthma.

The effect of exclusive exposure to ETS was limited to girls with asthma, who had deficits of 4% for MMEF associated with past ETS exposure. Combined exposure to maternal smoking in utero and ETS was associated with deficits that varied by children's asthma status. Among children without asthma, the percent decreases in measures of lung function were larger for combined exposure than for in utero exposure alone. Restriction of the combined-exposure category to current ETS and in utero exposure resulted in larger deficits in flows than for the category that included both past and current ETS exposure and in utero exposure (data not shown). Among children with asthma, combined exposure was associated with smaller deficits than was in utero exposure alone, especially among girls; however, the CIs were wide and the effects of combined exposure as compared with those of in utero exposure alone are uncertain on the basis of these data. Parental education, household income, insurance status, or personal smoking did not confound the relationship between combined effects of ETS and in utero exposure with lung function.

A growing body of evidence supports the concept that in utero exposure to maternal smoking can produce persistent deficits in childhood lung function, and that the deficits may be greater in children predisposed to asthma (4-6, 9, 11, 13, 15, 23, 24). Recent studies of lung function in newborns and infants of mothers who smoked during pregnancy show that in utero exposure to maternal smoking is associated with reduced lung function in the perinatal period (6, 9, 12, 13, 24). Studies among newborns in East Boston, Massachusetts, and Perth, Australia, which excluded effects of ETS by measuring lung function near birth, reported an independent effect of in utero exposure on respiratory mechanics (9, 12).

The perinatal deficits from in utero exposure to maternal smoking may be larger in children who subsequently develop asthma. Stick and colleagues reported that newborns with a family history of asthma had greater deficits in lung function from in utero exposure than did newborns without a family history of asthma (12). Our findings suggest that the perinatal deficits in lung function are persistent and large during adolescence. The large deficits may be important, because maternal smoking is also associated with a higher incidence of asthma, more severe disease, an earlier onset of disease, and an increased likelihood of using asthma medications (25). Other reports of the relationship between in utero exposure and lung function in children have not examined the variation in the association among boys and girls with and without asthma (4, 8, 15).

The deficits observed at birth appear to persist into childhood and adolescence, especially in measures associated with airway flow rates (4, 5, 26). The relative contribution to persistent deficits in lung function of in utero exposure to maternal smoking and postnatal ETS exposure is less clear (4, 5). In analyses of white children from 24 cities, Cunningham and associates reported that the effect of maternal smoking during pregnancy on measures of airway flows was greater than that for current smoking, and was not reduced by adjustment for current smoking (4). The effects of current smoking were small and were not significant after adjustment for smoking during pregnancy. A second study of inner-city children by the same group of investigators also suggested an independent effect of in utero exposure to maternal smoking (5). In contrast, studies conducted in the Netherlands and New Zealand reported either no effect of in utero exposure to maternal smoking or that the effects of ETS were independent of in utero exposure (27, 28). Our findings support the hypothesis that in utero exposure to maternal smoking is independently associated with persistent deficits in lung function, and indicate that children with asthma may be a sensitive group. Longitudinal studies done to determine whether the deficits associated with in utero exposure increase with time or asthma activity are warranted.

Although current ETS exposure is known to trigger and aggravate asthma attacks and to produce acute reductions in lung function, it is less certain that ETS exposure is independently associated with chronic deficits in lung function (29, 30). After accounting for the effect of in utero exposure, we observed an effect of past ETS exposure alone that was significant in girls without asthma. However, the lack of an association between ETS exposure and deficits in lung function among children with asthma may also be due to changes in ETS exposure subsequent to the development of asthma. Although we did not include smoking that occurred outside the house in our ETS exposure estimates, changes in the behavior of household smokers or in the affected child may have reduced ETS exposure and led to smaller estimates of effect.

The biologic mechanisms that account for the deficits associated with in utero exposure to maternal smoking among children with asthma have not been clarified. Because the airways are fully developed at birth, it may be that the small-airway deficits from in utero exposure reflect damage during critical periods of development that permanently alters the structure or function of the lung, such as its elastic recoil properties or immune function (15). Studies of rodents exposed to tobacco smoke during the in utero period show that newborns have increased bronchial reactivity (31). Increased bronchial reactivity may lead to both increased risk of asthma and deficits in small-airway flows. Because asthma is associated with deficits in flows, the effect of in utero exposure to maternal smoking may also be partly mediated by an increased occurrence of asthma. The effect may also be mediated by the increased occurrence of perinatal respiratory problems or early infections associated with in utero exposure (32).

Our study had some limitations. Asthma status was assigned on the basis of parental reports of a physician diagnosis of asthma. Parental reports have been shown to reflect physician diagnoses; however, the diagnosis of asthma by a physician depends on access to and utilization of medical care, and also on physician diagnostic practices (33, 34). Exposure to tobacco smoke was assessed retrospectively, using questionnaire responses, and was not validated by objective measurements. However, exposure estimates based on questionnaire responses have been validated (3, 35-38). We were unable to investigate any dose–response relationships for in utero exposure because we lacked information on the intensity or duration of exposure. We also lacked information on a number of potential confounders, such as maternal nutritional status and intake of alcohol or other potentially toxic substances during pregnancy. The pattern of ETS effects may have arisen from a differential measurement error for ETS as compared with in utero exposure. The measurement error for ETS is likely to be greater than that for in utero exposure, and may produce a larger bias toward the null for estimates of the effect of ETS.

Our findings have clinical and public health significance. The long-term effects of in utero exposure to maternal smoking on the growing lungs of children are of particular concern. If these deficits persist into adulthood, they may indicate increased risk for debilitating asthma and chronic obstructive pulmonary disease (32, 39-42). Reducing the long-term effects of tobacco smoke on children with asthma may require the reduction of smoking among women during their childbearing years.

In conclusion, we found that school-aged children with asthma show large deficits in lung function, especially airway flows, that are associated with in utero exposure to maternal smoking and that appear to be independent of ETS exposure. Because asthma itself is associated with chronic deficits in lung function, the additional deficits associated with in utero exposure to maternal smoking among children with asthma may indicate a group at high risk for adult chronic respiratory diseases. Further research is needed to clarify the roles of in utero exposure to maternal smoking and of asthma on lung growth and development.

Supported by Contract A033-186 with the California Air Resources Board, the grants: 1P01 ES09581-05 and 5P30 ES07048-02 from the National Institute of Environmental Health Sciences, the grant R826708-01-0 from the U.S. Environmental Protection Agency, grant 1 R01 HL61768-01 from the National Heart, Lung, and Blood Institute, and the Hastings Foundation.

1. U.S. Department of Health and Human Services. The health consequences of involuntary smoking. Washington, DC: U.S. Department of Health and Human Services; 1986. PHS Publication No. CDC87-8398.
2. U.S. Environmental Protection Agency. Respiratory health effects of passive smoking: lung cancer and other disorders, Washington, DC: U.S. Environmental Protection Agency; 1992.
3. California Environmental Protection Agency. Health effects of exposure to environmental tobacco smoke. Sacramento, CA: California Environmental Protection Agency; 1997.
4. Cunningham J, Dockery DW, Speizer EFMaternal smoking during pregnancy as a predictor of lung function in children. Am J Epidemiol139199411391152
5. Cunningham J, Dockery DW, Gold DR, Speizer FERacial differences in the association between maternal smoking during pregnancy and lung function in children. Am J Respir Crit Care Med1521995565569
6. Tager IB, Ngo L, Hanrahan JPMaternal smoking during pregnancy: effects on lung function during the first 18 months of life. Am J Respir Crit Care Med1521995977983
7. Haby MM, Peat JK, Woolcock AJEffect of passive smoking, asthma, and respiratory infection on lung function in Australian children. Pediatr Pulmonol181994323329
8. Cunningham J, O'Connor GT, Dockery DW, Speizer FEEnvironmental tobacco smoke, wheezing, and asthma in children in 24 communities. Am J Respir Crit Care Med1531996218224
9. Hanrahan JP, Tager IB, Segal MR, Tosteson TD, Castile RG, Van Vunakis H, Weiss ST, Speizer FEThe effect of maternal smoking during pregnancy on early infant lung function. Am Rev Respir Dis145199211291135
10. Tager IB, Segal MR, Munoz A, Weiss ST, Speizer FEThe effect of maternal cigarette smoking on the pulmonary function of children and adolescents: analyses of data from two populations. Am Rev Respir Dis136198713661370
11. Wang X, Wypij D, Gold DR, Speizer FE, Ware JH, Ferris BG, Dockery DWA longitudinal study of the effects of parental smoking on pulmonary function in children 6–18 years. Am J Respir Crit Care Med149199414201425
12. Stick SM, Burton PR, Gurrin L, Sly PD, LeSouef PNEffects of maternal smoking during pregnancy and a family history of asthma on respiratory function in newborn infants. Lancet348199610601064
13. Lodrup Carlsen KC, Jaakkola JJ, Nafstad P, and Carlsen KH. In utero exposure to cigarette smoking influences lung function at birth. Eur Respir J 1997;10:1774–1779.
14. Gilliland FD, Berhane K, McConnell R, Gauderman WJ, Vora H, Rappaport E, Avol E, Peters JMaternal smoking during pregnancy, environmental tobacco smoke exposure and children lung function. Thorax552000271276
15. Cook DG, Strachan DP, Carey IMParental smoking and spirometric indices in children. Thorax531998884893
16. Ulrik CSOutcome of asthma: longitudinal changes in lung function. Eur Respir J131999904918
17. Peters JM, Avol E, Gauderman WJ, Linn WS, Navidi W, London SJ, Margolis H, Rappaport E, Vora H, Gong H, et al.. A study of twelve Southern California communities with differing levels and types of air pollution: II. Effects on pulmonary function. Am J Respir Crit Care Med1591999768775
18. Peters JM, Avol E, Navidi W, London SJ, Gauderman WJ, Lurmann F, Linn WS, Margolis H, Rappaport E, Gong H, et al.. A study of twelve Southern California communities with differing levels and types of air pollution: I. Prevalence of respiratory morbidity. Am J Respir Crit Care Med1591999760767
19. Wypij D, Pugh M, Ware JHModeling pulmonary function growth with regression splines. Statist Sinica31994329350
20. Gold DR, Rotnitzky A, Damokosh AI, Ware JH, Speizer FE, Ferris BG, Dockery DWRace and gender differences in respiratory illness prevalence and their relationship to environmental exposures in children 7 to 14 years of age. Am Rev Respir Dis14819931018
21. Hastie TJ, Tibshirani RJVarying-coefficient models (with discussion). J R Statist Soc B551993757796
22. Becker RA, Chambers JM. The new S language. Pacific Grove, CA: Wadsworth and Brooks/Cole; 1988.
23. Tager IB, Hanrahan JP, Tosteson TD, Castile RG, Brown RW, Weiss ST, Speizer FELung function, pre- and post-natal smoke exposure, and wheezing in the first year of life. Am Rev Respir Dis1471993811817
24. Hanrahan JP, Halonen MAntenatal interventions in childhood asthma. Eur Respir J Suppl27199846s51s
25. Weitzman M, Gortmaker S, Walker DK, Sobol AMaternal smoking and childhood asthma. Pediatrics851990505511
26. Jedrychowski W, Flak E[Cigarette smoking of mothers in pregnancy and environmental tobacco smoke as factors of increasing susceptibility of older children to acute respiratory infections]. Przegl Epidemiol501996457465
27. Sherrill DL, Martinez FD, Lebowitz MD, Holdaway MD, Flannery EM, Herbison GP, Stanton WR, Silva PA, Sears MRLongitudinal effects of passive smoking on pulmonary function in New Zealand children. Am Rev Respir Dis145199211361141
28. Dijkstra L, Houthuijs D, Brunekreef B, Akkerman I, Boleij JSRespiratory health effects of the indoor environment in a population of Dutch children. Am Rev Respir Dis142199011721178
29. Murray AB, Morrison BJPassive smoking and the seasonal difference of severity of asthma in children. Chest941988701708
30. Knight A, Breslin ABPassive cigarette smoking and patients with asthma. Med J Aust1421985194195
31. Joad JP, Bric JM, Peake JL, Pinkerton KEPerinatal exposure to aged and diluted sidestream cigarette smoke produces airway hyperresponsiveness in older rats. Toxicol Appl Pharmacol1551999253260
32. Dezateux C, Stocks JLung development and early origins of childhood respiratory illness. Br Med Bull5319974057
33. Burr ML, St. Leger AS, Bevan C, Merrett TGA community survey of asthmatic characteristics. Thorax301975663668
34. Dodge RR, Burrows BThe prevalence and incidence of asthma and asthma-like symptoms in a general population sample. Am Rev Respir Dis1221980567575
35. Ronchetti R, Bonci E, de Castro G, Signoretti F, Macri F, Ciofetta GC, Villa MP, Indinnimeo L, Martinez FDRelationship between cotinine levels, household and personal smoking habit and season in 9–14 year old children. Eur Respir J71994472476
36. Oryszczyn MP, Godin J, Annesi I, Hellier G, Kauffmann FIn utero exposure to parental smoking, cotinine measurements, and cord blood IgE. J Allergy Clin Immunol87199111691174
37. Coultas DB, Peake GT, Samet JMQuestionnaire assessment of lifetime and recent exposure to environmental tobacco smoke. Am J Epidemiol1301989338347
38. Coultas DB, Samet JM, McCarthy JF, Spengler JDVariability of measures of exposure to environmental tobacco smoke in the home. Am Rev Respir Dis1421990602606
39. Burrows B, Taussig LM“As the twig is bent, the tree inclines” (perhaps). Am Rev Respir Dis1221980813816
40. Sherrill DL, Lebowitz MD, Knudson RJ, Burrows BSmoking and symptom effects on the curves of lung function growth and decline. Am Rev Respir Dis14419911722
41. Tager IB, Weiss ST, Munoz A, Rosner B, Speizer FELongitudinal study of the effects of maternal smoking on pulmonary function in children. N Engl J Med3091983699703
42. Tager IB, Segal MR, Speizer FE, Weiss STThe natural history of forced expiratory volumes: effect of cigarette smoking and respiratory symptoms. Am Rev Respir Dis1381988837849
Correspondence and requests for reprints should be addressed to Frank Gilliland, Department of Preventive Medicine, USC Keck School of Medicine, 1540 Alcazar Street, CHP 236, Los Angeles, CA 90033. E-mail:

The statements and conclusions in this report are those of the investigators and not necessarily those of the California Air Resources Board, the U.S. Environmental Protection Agency, or the National Institute of Environmental Health Sciences. The mention of commercial products, their source, or their use in connection with material reported herein is not to be construed as either an actual or implied endorsement of such products.

Related

No related items
American Journal of Respiratory and Critical Care Medicine
162
6

Click to see any corrections or updates and to confirm this is the authentic version of record